Gan & Lee Pharmaceuticals.

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 11/12/2025			5-day change	1st Jan Change
65.27 ^CNY	+1.95%		+5.36%	+48.00%

12-09	Gan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug	MT
11-18	Gan & Lee Pharmaceuticals Europe GmbH Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Recommends the Approval of Insulin Glargine Injection	CI

Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.

Published on 01/02/2025

S&P Capital IQ

Gan & Lee Pharmaceuticals.

+1.95%

From October 1, 2024 to December 31, 2024, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 396,900 shares, representing 0.07% for CNY 15.13 million under the buyback announced on September 6, 2024.

Latest news about Gan & Lee Pharmaceuticals.

12-09	Gan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug	MT
11-18	Gan & Lee Pharmaceuticals Europe GmbH Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Recommends the Approval of Insulin Glargine Injection	CI
10-30	Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
10-17	Gan & Lee Pharmaceuticals Appoints Dr. Ting Jia as Chief Medical Officer	CI
09-29	Gan & Lee Pharmaceuticals Signs National "Technology Transfer and Supply Agreement" in Brazil to Accelerate Local Insulin Manufacturing	CI
09-23	Gan & Lee Pharmaceuticals signs framework agreement	RE
09-07	Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	CI
09-07	Gan & Lee Pharmaceuticals.'s Equity Buyback announced on September 6, 2024, has expired with 3,540,021 shares, representing 0.6% for CNY 150.07 million	CI
08-08	Gan & Lee Pharmaceuticals' lH1 Profit Jumps 103%, Revenue Rises 57%	MT
08-07	Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
08-07	Gan & Lee Pharmaceuticals' H1 net profit up 102.0% Y/Y	RE
07-09	Gan & Lee Pharmaceuticals sees H1 net profit up 100.7-114.1% Y/Y	RE
07-08	Gan & Lee Pharmaceuticals' Insulin Aspart Receives Approval in Argentina	CI
06-21	Gan & Lee Pharmaceuticals Presents Multiple Results in Novel Diabetes Therapies At the American Diabetes Association's 85Th Scientific Sessions	CI
05-19	Gan & Lee Pharmaceuticals Completes First Patient Dosing in GZR102 Trial	MT
04-25	Gan & Lee Pharmaceuticals' 2024 Profit Jumps 81%, Operating Income Rises 17%; Shares Jump 10%	MT
04-25	Gan & Lee Pharmaceuticals' Q1 Profit Surged 225%, Operating Income Jumps 76%; Shares Jump 10%	MT
04-24	Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
04-23	Gan & Lee Pharmaceuticals Gets Nod to Trial Diabetes Drug	MT
04-02	Gan & Lee Pharma's Insulin Glargine Injection Gets Registration Nod in Pakistan	MT
04-01	Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	CI
03-11	Gan & Lee Pharmaceuticals Doses First Subject for Phase II Clinical Trial of Bovanglutide Injection	MT
03-10	Gan & Lee Pharmaceuticals Announces First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide Injection for Overweight or Obesity	CI
02-18	Gan & Lee Pharma Doses First Subject for Insulin Drug's Phase III Trial; Shares Up 3%	MT
02-11	Gan & Lee Pharmaceuticals Registers Diabetes Treatment Drug	MT

Chart Gan & Lee Pharmaceuticals.

Duration

Period

603087: Dynamic Chart

Company Profile

Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.

Employees

5,245

Sector

Pharmaceuticals

Calendar

04-22 - Q4 2025 Earnings Release (Projected)

More about the company